MAP2K5

Across TCGA pan-cancer cohorts, MAP2K5 mass-spec protein differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of MAP2K5’s most consistent transcriptional readouts.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where MAP2K5 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types MAP2K5 is over-expressed in tumor, although a few such as PDAC and LUAD show the opposite, repressed pattern.

PDAC, LUAD, and HNSC are the cancer types where MAP2K5 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAP2K5 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
PDAC	Male	All	−0.563	<.001	7	view →
LUAD	Female	All	−0.225	<.001	6	view →
HNSC	Male	All	+0.206	<.001	6	view →
LSCC	Female	II,III,IV	−0.233	<.001	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

MAP2K5–PDAC

Open the PDAC breakdown →